<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> cells suspensions prepared from 129 B- or non-T cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> were investigated with a panel of 10 monoclonal antibodies and conventional surface marker techniques </plain></SENT>
<SENT sid="1" pm="."><plain>Surface immunoglobulin (sIg) and B1 antigen proved to be the most useful markers for B-cell lineage </plain></SENT>
<SENT sid="2" pm="."><plain>Six major subtypes of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) of non-T cell nature are now recognized by these immunological techniques, including null-ALL, Ia-ALL, lymphoid stem cell ALL, <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-pre-B ALL</z:e>, <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-B ALL</z:e> and <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In cases of <z:hpo ids='HP_0005558'>chronic leukemias</z:hpo> and <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of non-T cell nature, 80% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was defined by sIg and 88% by B1 antigen as definitely of B-cell lineage </plain></SENT>
<SENT sid="4" pm="."><plain>The clonal character was also defined in 68% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> on the basis of the detection of predominant single light chain in sIg </plain></SENT>
<SENT sid="5" pm="."><plain>Ia-like antigen was detected in almost <z:hpo ids='HP_0000001'>all</z:hpo> cases (96%) </plain></SENT>
<SENT sid="6" pm="."><plain>Leukemic cells from <z:hpo ids='HP_0000001'>all</z:hpo> cases of <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL), <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0079734" disease_type="Neoplastic Process" abbrv="">lymphosarcoma</z:e> cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CLsCL) and hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (HCL) reacted with OKIa1 and anti-B1, and leukemic cells from most of them with anti-pan T monoclonal antibody (10.2) </plain></SENT>
<SENT sid="7" pm="."><plain>In more than half of CLL and CLsCL, leukemic cells were reactive with J5, OKM1, 9.6 and OKT8, but not with OKT3, OKT4 and OKT6 </plain></SENT>
<SENT sid="8" pm="."><plain>HCL cells had almost the same reactivity with these monoclonal antibodies as CLL and CLsCL cells except that J5 remained unreactive </plain></SENT>
<SENT sid="9" pm="."><plain>These results indicated that Japanese CLL, CLsCL and HCL were different from Western ones at least with respect to surface marker characteristics </plain></SENT>
<SENT sid="10" pm="."><plain>In cases of <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, heavy chains of sIg were expressed in polyclonal fashion, especially in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and diffuse <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of medium sized cell type and large cell type, indicating that <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of these types may originate from follicular center cells of the heavy chain switching stage </plain></SENT>
<SENT sid="11" pm="."><plain>Anti-T monoclonals were also reactive with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="12" pm="."><plain>In about half of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and diffuse <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of the medium sized cell type, <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells reacted with 10.2, and less frequently with 9.6, OKT4 and OKT3 </plain></SENT>
<SENT sid="13" pm="."><plain>On the other hand, only in one or two cases of diffuse <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the large cell type and of <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>), did <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells react with 10.2 and 9.6, but this was exceptional </plain></SENT>
<SENT sid="14" pm="."><plain>In more than 25% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IBS</z:e>, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells also reacted with OKT8, but not with OKT4 and OKT3 </plain></SENT>
<SENT sid="15" pm="."><plain>These results indicated that anti-T monoclonals are no longer specific for T-cell lineage.(ABSTRACT TRUNCATED AT 400 WORDS) </plain></SENT>
</text></document>